Leerink Reiterates Outperform rating on Incyte Corporation(NASDAQ:INCY) Here is Why
Equity Analysts Michael Schmidt, Ph.D.and Jonathan Chang, Ph.D.of Investment Research Firm Leerink Partners LLC issued a research report and reiterated their outperform rating on Incyte Corporation(NASDAQ:INCY) titled ”3rd Baricitinib Trial Positive, One to Go; Buy the Pullback” on September 29. The report stated that ”Bottom Line: INCY and LLY (OP)[Read More…]